Biofrontera Net Income From Continuing Ops from 2010 to 2024

BFRI Stock  USD 0.92  0.05  5.75%   
Biofrontera's Net Loss is decreasing with slightly volatile movements from year to year. Net Loss is predicted to flatten to about -27.8 M. For the period between 2010 and 2024, Biofrontera, Net Loss quarterly trend regression had median of (10,982,000) and r-value of (0.46). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-26.4 M
Current Value
-27.8 M
Quarterly Volatility
9.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biofrontera financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biofrontera's main balance sheet or income statement drivers, such as Tax Provision of 33 K, Interest Income of 90.6 K or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 0.12, Dividend Yield of 0.0 or PTB Ratio of 0.85. Biofrontera financial statements analysis is a perfect complement when working with Biofrontera Valuation or Volatility modules.
  
Check out the analysis of Biofrontera Correlation against competitors.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.

Latest Biofrontera's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Biofrontera over the last few years. It is Biofrontera's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biofrontera's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Biofrontera Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(14,224,407)
Coefficient Of Variation(64.66)
Mean Deviation6,566,117
Median(10,982,000)
Standard Deviation9,198,043
Sample Variance84.6T
Range37.1M
R-Value(0.46)
Mean Square Error71.8T
R-Squared0.21
Significance0.08
Slope(948,085)
Total Sum of Squares1184.5T

Biofrontera Net Income From Continuing Ops History

2024-27.8 M
2023-26.4 M
2022-640 K
2021-37.7 M
2020-11 M

About Biofrontera Financial Statements

Investors use fundamental indicators, such as Biofrontera's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Biofrontera's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Loss-26.4 M-27.8 M

Currently Active Assets on Macroaxis

When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:
Check out the analysis of Biofrontera Correlation against competitors.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.16
Revenue Per Share
11.573
Quarterly Revenue Growth
0.34
Return On Assets
(0.40)
Return On Equity
(1.49)
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.